View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Bausch Health Companies Inc.: Appellate ruling alleviates pressure, bu...

Our credit view of this issuer reflects its good free cash flow prior to any generic Xifaxan launch, offset by its high financial leverage and untenable capital structure.

Bausch Health Companies Inc.: Key facts and statistics - 2023

A summary company profile, detailing Bausch Health Companies Inc.’s business operations and financial highlights.

Bausch Health Companies Inc.: Credit profile constrained by generic Xi...

Our credit view of this issuer reflects its good free cash flow prior to any generic XIfaxan launch, offset by its high financial leverage and untenable capital structure.

Bausch Health Companies Inc.: Credit profile constrained by generic Xi...

Our credit view of this issuer reflects its good free cash flow prior to any generic XIfaxan launch, offset by its high financial leverage and untenable capital structure.

Bausch Health Companies Inc.: Update following completion of distresse...

Our credit view of this issuer reflects its high financial leverage and untenable capital structure given risks related to potential Xifaxan generic competition

Bausch Health Companies Inc.: Update following downgrade to Caa2

Our credit view of this issuer reflects high potential for debt restructuring deemed to be a distress exchange, the potential genericization of Xifaxan, and high financial leverage.

Bausch Health Companies Inc.: Update following downgrade to Caa1

Our credit view of this issuer reflects its large global scale and good margins, tempered by high financial leverage and exposure to generic competition on its largest drug

Bausch Health Companies Inc.: Update following IPO of Bausch + Lomb

Our credit view of this issuer reflects its status as a large specialty pharmaceutical and healthcare company with strong product diversity, constrained by its high financial leverage.

Bausch Health Companies Inc.: Progressing toward Bausch + Lomb spin-of...

Our credit view of this issuer reflects its status as a large specialty pharmaceutical and healthcare company with strong product diversity, constrained by its high financial leverage.

Moody's assigns Ba3 to Bausch Health's secured notes; outlook negative

Rating Action: Moody's assigns Ba3 to Bausch Health's secured notes; outlook negative. Global Credit Research- 27 Jan 2022. New York, January 27, 2022-- Moody's Investors Service assigned a Ba3 rating to the new senior secured notes issuance of Bausch Health Companies Inc..

Moody's assigns Ba3 to Bausch Health's senior secured credit facilitie...

Rating Action: Moody's assigns Ba3 to Bausch Health's senior secured credit facilities; outlook negative. Global Credit Research- 18 Jan 2022. New York, January 18, 2022-- Moody's Investors Service assigned a Ba3 rating to the new senior secured term loan and revolving credit facility of Bausch Health Companies Inc..

Bausch Health Companies Inc.: Update to credit analysis following outl...

Our credit view of this issuer reflects its large global scale and diversity, constrained by its high financial leverage and the upcoming spinoff of the global vision business.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch